aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism.
Role of NRP2 in immune system validated by activity of NRP2 blocking antibody in preclinical models.
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present two posters at the Keystone Symposia on Myeloid Cell Diversity: From Fundamental Biology to Disease States, which is being held January 28 – 31, 2024, in Banff, Alberta, Canada.
“The findings presented in these posters contribute to the growing body of evidence regarding the role of NRP2 in the immune response,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Notably, this data enhances our mechanistic understanding of the way in which efzofitimod is providing the anti-inflammatory benefits seen in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), and suggest that this therapy may represent a breakthrough in the treatment of diseases such as ILD where myeloid cells play a critical role in pathogenesis and disease progression.”
Details of the presentations appear below. The posters will be available on the aTyr website once presented.
Title: Demonstration of an Isoform-Specific Anti-inflammatory Role for Neuropilin-2 Through a Novel Interaction with the Chemokine Ligand 21
Authors: Luke G. Burman, Christoph Burkart, Clara Polizzi, Max Pastenes, Yeeting E. Chong, Cole Link, Kaitlyn Rauch, Ann Menefee, Yang Qing, Gertrud Malene Hjortø, Leslie A. Nangle. aTyr Pharma, San Diego; Faculty of Health and Medical Sciences, Copenhagen, Denmark.
Poster Number: 1012
Session: Poster Session 1
Date and Time: Monday, January 29, 2024, at 7:30 p.m. PST
Title: Efzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor
Authors: David Siefker, Zhiwen Xu, Annie Wang, Sofia Klopp-Savino, Kaitlyn Rauch, Lauren Guy, Sheeraz Un Nazir, Yeeting E. Chong, Samikshan Dutta, Ryan Adams, Kaustubh Datta, Leslie Nangle. aTyr Pharma, San Diego; University of Nebraska Medical Center, Omaha.
Poster Number: 2027
Session: Poster Session 2
Date and Time: Tuesday, January 30, 2024, at 6:30 p.m. PST
About Efzofitimod
Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
